ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Levomilnacipran

Also written as “Levomilnacipran ER”, “F2695” and “Levomilnacipran Hydrochloride Extended-Release Capsules”.

Its studies are mostly in Depressive Disorder, Major · Depression · Ischemic Stroke, led by 3 companies.

Drug pageLevomilnacipran: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Nov 7, 201413 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVieits history only100 open or runningphase 4since Nov 7, 2014Aug 31, 2009none ahead
Pierre Fabre20 open or runningphase 3since Jul 10, 2012Jul 10, 2012none ahead
Zhejiang Huahai Pharmaceuticalits history only10 open or runningphase 3since Nov 18, 2025Nov 18, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Pierre Fabre only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 10, 2012First study: phase 3 study in Ischemic StrokeFirst studyNCT01639014 · 532 enrolled · Belgium, Czech Republic, France and more
  2. Sep 19, 2014Phase 1 study in SubjectNCT02266966 · 17 enrolled · France

TargetBeta

“Serotonin transporter inhibitor; Norepinephrine transporter inhibitor”ChEMBL 37, by rule

Studies

All 2 Pierre Fabre leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02266966Subject · France1CompletedSep 201417
NCT01639014Ischemic Stroke · Belgium, Czech Republic, France and more3CompletedFeb 2015532

How it is read

Names in the registry

  • “Levomilnacipran ER”, 11 entries
  • “F2695”, 2 entries
  • “Levomilnacipran Hydrochloride Extended-Release Capsules”, 1 entry
  • “Levomilnacipran”, 1 entry
  • “F2695 SR”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.